Expand chart
Data: Centers for Medicare & Medicaid Services' Office of the Actuary; Chart: Axios Visuals

Spending on prescription drugs in 2018 — both through premiums and out-of-pocket costs — grew a moderate 2.5% from the previous year, which was below the growth rates for hospital and doctor services.

Yes, but: That doesn't give a true accounting of total pharmaceutical spending. Spending on common and expensive drugs that are administered by providers is buried within the hospital and doctor statistics.

The big picture: Retail prescription spending stayed relatively low last year because more people used cheaper generic drugs, and because price increases were held in check, actuaries wrote in the government's report.

  • Companies have still been raising the list prices of their medicines to offset the rise in drug rebates, but the political climate has prevented companies from instituting large, frequent price increases like previous years.

But retail drug spending, which totaled $335 billion in 2018, does not factor in inpatient pharmacies, chemotherapy, infusions and other drugs that people have to receive in a hospital or clinic — drugs that equal a quarter of the entire pharmaceutical market.

  • That means spending on blockbusters like Rituxan, Opdivo, Keytruda, Eylea, Neulasta, Remicade and Lucentis is nestled within the hospital and physician data.
  • Together, those seven drugs generated $26 billion in net U.S. sales in 2018, according to company financial reports analyzed by Axios — a 12% spike from 2017.
  • Adding just those seven drugs to retail prescription spending pushes 2018's annual growth rate up to 3.1%.

The bottom line: The federal government's report on national health spending is essential reading, but it takes extra work to get the full picture of the money we spend on all drugs.

Go deeper

2 hours ago - Podcasts

The child care tax on America's economy

Child care in the U.S. is in crisis, which makes it much harder for the American economy to recover — as providers struggle to stay in business and parents wrestle with work.

Axios Re:Cap digs into the problems and what can be done to solve them, with Vox senior reporter Anna North.

Viral load is a puzzle in COVID-19

Illustration: Eniola Odetunde/Axios

How sick a person gets from a virus can depend on how much of the pathogen that person was exposed to and how much virus is replicating in their body — questions that are still open for the novel coronavirus.

Why it matters: As people try to balance resuming parts of their daily lives with controlling their risk of COVID-19, understanding the role of viral load could help tailor public health measures and patient care.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 4 p.m. EST: 32,048,333 — Total deaths: 979,454 — Total recoveries: 22,025,324Map.
  2. U.S.: Total confirmed cases as of 4 p.m EST: 6,962,333 — Total deaths: 202,467 — Total recoveries: 2,670,256 — Total tests: 97,459,742Map.
  3. Health: Cases are surging again in 22 states — New York will conduct its own review of coronavirus vaccine.
  4. Business: America is closing out its strongest quarter of economic growth.
  5. Technology: 2020 tech solutions may be sapping our resolve to beat the pandemic.
  6. Sports: Here's what college basketball will look like this season.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Subscription failed
Thank you for subscribing!